The EU-Solidact baricitinib trial is an inpatient-only trial, and cannot be joined by individuals outside the hospitals who are members of the trial. If you are a patient admitted to hospital for COVID-19, and your hospital is a member of the trial, you will automatically be evaluated for participation, and if you meet the criteria, offered a place in the trial. As such, there is no central email address for patients to contact the trial itself.

If you are a patient who has been part of the SolidAct trial, and you wish to get in touch with the trial organisers, please contact the doctor who treated you while you were an inpatient at the hospital. The information you need should be contained in the informed consent form you signed before you entered the trial.

More information about the Bari-SolidAct trial may be found on the main EU-Response website.